Kezar Life Sciences Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Kezar Life Sciences, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.007.000.000.000.000.000.00
Cost of Revenue1.0485.7051.0138.940.000.000.00
Gross Profit-1.04-78.70-51.01-38.940.000.000.00
Operating Expenses
Research & Development65.7485.7051.0138.9430.9827.3618.14
Selling, General & Administrative23.3926.5420.1515.7211.979.986.59
Operating Expenses90.6126.5471.1654.6642.9537.3424.73
Operating Income-90.61-105.24-71.16-54.66-42.95-37.34-24.73
Other Income/Expense
Interest Income8.4611.104.110.191.210.001.56
Interest Expense1.59-1.551.19-0.160.000.000.00
Other Income/Expense6.87-6.190.000.000.000.000.00
Income
Income Before Tax-83.74-101.87-68.24-54.63-41.74-35.09-23.17
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-83.74-101.87-68.24-54.63-41.74-35.09-23.17
Net Income - Continuous Operations-83.74-101.87-68.24-54.630.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-81.10-104.17-66.03-52.96-40.20-34.77-24.04
EBIT-83.74-105.24-67.05-54.47-41.74-35.09-24.73
Depreciation & Amortization1.041.071.020.900.900.900.00
Earnings Per Share
Basic EPS-1.00-14.00-10.00-10.00-9.00-18.00-2.00
Diluted EPS-1.00-14.00-10.00-10.00-9.00-18.00-2.00
Basic Shares Outstanding72.907.266.745.284.401.9110.26
Diluted Shares Outstanding72.907.266.745.284.401.9110.26